Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana, Havana, Cuba.
Department of Microbiology and Immunobiology of Harvard Medical School, Harvard University, Boston, MA, United States.
Front Immunol. 2018 Nov 5;9:2473. doi: 10.3389/fimmu.2018.02473. eCollection 2018.
Cross-presentation is an important mechanism for the differentiation of effector cytotoxic T lymphocytes (CTL) from naïve CD8 T-cells, a key response for the clearance of intracellular pathogens and tumors. The liposomal co-encapsulation of the pore-forming protein sticholysin II (StII) with ovalbumin (OVA) (Lp/OVA/StII) induces a powerful OVA-specific CTL activation and an anti-tumor response . However, the pathway through which the StII contained in this preparation is able to induce antigen cross-presentation and the type of professional antigen presenting cells (APCs) involved have not been elucidated. Here, the ability of mouse bone marrow-derived dendritic cells (BM-DCs) and macrophages (BM-MΦs) stimulated with Lp/OVA/StII to activate SIINFEKL-specific B3Z CD8 T cells was evaluated in the presence of selected inhibitors. BM-MΦs, but not BM-DCs were able to induce SIINFEKL-specific B3Z CD8 T cell activation upon stimulation with Lp/OVA/StII. The cross-presentation of OVA was markedly decreased by the lysosome protease inhibitors, leupeptin and cathepsin general inhibitor, while it was unaffected by the proteasome inhibitor epoxomicin. This process was also significantly reduced by phagocytosis and Golgi apparatus function inhibitors, cytochalasin D and brefeldin A, respectively. These results are consistent with the concept that BM-MΦs internalize these liposomes through a phagocytic mechanism resulting in the cross-presentation of the encapsulated OVA by the vacuolar pathway. The contribution of macrophages to the CTL response induced by Lp/OVA/StII was determined by depleting macrophages with clodronate-containing liposomes. CTL induction was almost completely abrogated in mice depleted of macrophages, demonstrating the relevance of these APCs in the antigen cross-presentation induced by this formulation.
交叉呈递是效应细胞毒性 T 淋巴细胞(CTL)从幼稚 CD8 T 细胞分化的重要机制,是清除细胞内病原体和肿瘤的关键反应。孔形成蛋白溶血素 II(StII)与卵清蛋白(OVA)的脂质体共包封(Lp/OVA/StII)诱导强大的 OVA 特异性 CTL 激活和抗肿瘤反应。然而,该制剂中包含的 StII 诱导抗原交叉呈递的途径以及涉及的专业抗原呈递细胞(APC)类型尚未阐明。在这里,评估了用 Lp/OVA/StII 刺激的小鼠骨髓来源树突状细胞(BM-DC)和巨噬细胞(BM-MΦ)激活 SIINFEKL 特异性 B3Z CD8 T 细胞的能力,同时使用了选定的抑制剂。BM-MΦ,而不是 BM-DC,在受到 Lp/OVA/StII 刺激后能够诱导 SIINFEKL 特异性 B3Z CD8 T 细胞激活。溶酶体蛋白酶抑制剂亮抑酶肽和组织蛋白酶通用抑制剂显着降低了 OVA 的交叉呈递,而蛋白酶体抑制剂环氧酶素则不受影响。该过程也分别被吞噬作用和高尔基体功能抑制剂细胞松弛素 D 和布雷菲德菌素 A 显著降低。这些结果与巨噬细胞通过吞噬作用机制内化这些脂质体的概念一致,导致囊泡途径中包裹的 OVA 的交叉呈递。用含有氯膦酸盐的脂质体耗尽巨噬细胞来确定巨噬细胞对 Lp/OVA/StII 诱导的 CTL 反应的贡献。在用巨噬细胞耗尽的小鼠中,CTL 诱导几乎完全被阻断,这表明这些 APC 在该制剂诱导的抗原交叉呈递中具有相关性。